ETON
Eton Pharmaceuticals Inc
55.20$
+0.8%
vs. previous close
Closing price · As of: Oct 9, 2026
Statements
Income Statement
All figures as a percentage of revenue in the same period.
Tick rows to compare them in a chart (up to 4)
| Line item | Q2 17 | Q3 17 | Q4 17 | Q1 18 | Q2 18 | Q3 18 | Q4 18 | Q1 19 | Q2 19 | Q3 19 | Q4 19 | Q1 20 | Q2 20 | Q3 20 | Q4 20 | Q1 21 | Q2 21 | Q3 21 | Q4 21 | Q1 22 | Q2 22 | Q3 22 | Q4 22 | Q1 23 | Q2 23 | Q3 23 | Q4 23 | Q1 24 | Q2 24 | Q3 24 | Q4 24 | Q1 25 | Q2 25 | Q3 25 | Q4 25 | Q1 26 | Q2 26 | LTM* |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| – | – | – | – | – | – | – | 100.0% | – | – | 100.0% | 100.0% | 100.0% | – | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | 100.0% | |
| – | – | – | – | – | – | – | 0.0% | – | – | 98.7% | 103.0% | 140.0% | – | 370.4% | 13.4% | 4.4% | 79.6% | 4.6% | 33.0% | 37.3% | 37.3% | 25.2% | 36.9% | 19.3% | 37.4% | 50.4% | 37.1% | 38.0% | 39.0% | 44.4% | 42.9% | 37.0% | 65.0% | 38.4% | 39.3% | 32.4% | 42.1% | |
| – | – | – | – | – | – | – | 100.0% | – | – | 1.3% | -3.0% | -40.0% | – | -270.4% | 86.6% | 95.6% | 20.4% | 95.4% | 67.0% | 62.7% | 62.7% | 74.8% | 63.1% | 80.7% | 62.6% | 49.6% | 62.9% | 62.0% | 61.0% | 55.6% | 57.1% | 63.0% | 35.0% | 61.6% | 60.7% | 67.6% | 57.9% | |
| – | – | – | – | – | – | – | 1,293.0% | – | – | 50.8% | 6,331.3% | 8,045.0% | – | 4,198.8% | 7.4% | 64.9% | 345.5% | 11.2% | 74.4% | 9.4% | 23.1% | 11.1% | 10.1% | 9.4% | 8.8% | 14.3% | 8.2% | 32.7% | 4.9% | 7.5% | 6.7% | 19.6% | 5.0% | 8.4% | 7.7% | 2.6% | 5.5% | |
| – | – | – | – | – | – | – | 317.8% | – | – | 529.2% | 2,636.4% | 14,605.0% | – | 4,691.4% | 34.1% | 106.5% | 429.3% | 62.7% | 226.4% | 71.5% | 129.5% | 51.2% | 100.8% | 39.0% | 61.7% | 62.6% | 64.7% | 61.6% | 51.2% | 57.7% | 53.1% | 51.2% | 36.1% | 41.6% | 43.0% | 30.9% | 37.0% | |
| – | – | – | – | – | – | – | 1,610.8% | – | – | 580.0% | 8,967.7% | 22,650.0% | – | 8,890.1% | 41.6% | 171.4% | 774.8% | 73.8% | 300.8% | 80.9% | 152.6% | 62.3% | 110.9% | 48.3% | 70.4% | 76.9% | 72.9% | 94.3% | 56.1% | 50.2% | 59.8% | 70.8% | 41.0% | 50.0% | 50.8% | 33.6% | 42.4% | |
| – | – | – | – | – | – | – | -1,510.8% | – | – | -578.6% | -8,970.7% | -22,690.0% | – | -9,160.5% | 45.1% | -75.8% | -754.5% | 21.6% | -233.8% | -18.2% | -89.9% | 12.5% | -47.8% | 32.4% | -7.8% | -27.3% | -10.0% | -32.3% | 4.9% | 5.4% | -2.7% | -7.8% | -6.1% | 11.6% | 9.9% | 34.0% | 15.4% | |
| – | – | – | – | – | – | – | 28.8% | – | – | 8.7% | 169.7% | 960.0% | – | 332.1% | 2.1% | 7.7% | 31.9% | 4.5% | 11.2% | 3.0% | 4.7% | 3.0% | 2.4% | 1.0% | 0.4% | 4.9% | 0.1% | 0.6% | 0.1% | 11.4% | 6.7% | 6.3% | 5.4% | 5.7% | 3.5% | 2.9% | 4.1% | |
| – | – | – | – | – | – | – | -1,482.0% | – | – | -587.4% | -9,140.4% | -23,650.0% | – | -9,490.1% | 43.0% | -65.7% | -786.3% | 17.1% | -244.9% | -21.2% | -94.6% | 10.7% | -50.2% | 38.0% | -8.2% | -27.5% | -10.2% | -32.9% | 4.9% | -4.4% | -8.7% | -13.3% | -8.7% | 6.6% | 6.5% | 31.2% | 12.1% | |
| – | – | – | – | – | – | – | 0.0% | – | – | -32.2% | – | – | – | -198.8% | – | -10.1% | 0.5% | 4.5% | 11.2% | 3.0% | 4.7% | -1.2% | 4.8% | 5.9% | 3.4% | 3.4% | 2.6% | 0.6% | -1.2% | 0.7% | 0.4% | 0.3% | -0.1% | -0.3% | 0.1% | 0.4% | 0.1% | |
| – | – | – | – | – | – | – | -1,482.0% | – | – | -587.4% | -9,140.4% | -23,650.0% | – | -9,490.1% | 43.0% | -65.7% | -786.3% | 17.1% | -244.9% | -21.2% | -94.6% | 10.7% | -50.2% | 38.0% | -8.2% | -30.8% | -10.2% | -33.5% | 6.1% | -5.1% | -9.1% | -13.7% | -8.6% | 7.0% | 6.4% | 30.8% | 12.0% | |
| – | – | – | – | – | – | – | -1,499.8% | – | – | -546.4% | -8,807.1% | -21,870.0% | – | -8,961.7% | 46.4% | -55.2% | -743.5% | 23.8% | -225.5% | -2.3% | -84.7% | 16.7% | -43.8% | 40.5% | -5.1% | -34.4% | -7.1% | -29.3% | 7.6% | -1.3% | 3.9% | -1.7% | 1.2% | 17.1% | 7.7% | 37.7% | 18.9% |
LTM = last twelve months (sum of the four most recent quarters).
Data as of: October 9, 2026 · Source: fundamental data & SEC filings (annual and quarterly reports, 10-K/10-Q)
Note: pure fact-based analysis, not investment advice and not a solicitation to buy or sell. All figures without guarantee.